A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604)

BACKGROUND: Standard chemotherapy for poor-prognosis metastatic nonseminoma has remained bleomycin, etoposide, and cisplatin (BEP) for many years; more effective regimens are required. OBJECTIVE: To explore whether response rates with a new intensive chemotherapy regimen, CBOP/BEP (carboplatin, bleo...

Descripción completa

Detalles Bibliográficos
Autores principales: Huddart, Robert A., Gabe, Rhian, Cafferty, Fay H., Pollock, Philip, White, Jeff D., Shamash, Jonathan, Cullen, Michael H., Stenning, Sally P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2015
Materias:
Platinum Priority – Testis Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410298/
https://www.ncbi.nlm.nih.gov/pubmed/25001888
http://dx.doi.org/10.1016/j.eururo.2014.06.034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410298/
https://www.ncbi.nlm.nih.gov/pubmed/25001888
http://dx.doi.org/10.1016/j.eururo.2014.06.034

Ejemplares similares